Journalist @swissinfo_en covering multinationals, #bigpharma, biotechs, workplace. Bay Area native in Switzerland. Circus performer in another life.
Joined January 2010
- Tweets 1,386
- Following 601
- Followers 571
- Likes 1,238
25 Photos and videos
Pinned Tweet
1 Nov 2022
First two stories from Kenya on what it takes to get “innovative medicines” for cancer and genetic diseases to the world. Price is clearly not the only barrier to access life-saving medicine but it’s a big one. More on this: swissinfo.ch/eng/the-end-of-…
1
11
18
Jessica Davis Pluess retweeted
18 Dec 2025
As the pharma industry turns away, parents of children with ultra-rare diseases step in to advance drug development. But the funding challenges are immense even in a wealthy country like Switzerland. buff.ly/hPbohnk #rarediseases #genetherapy
1
3
583
Jessica Davis Pluess retweeted
27 May 2025
The World Health Organization (WHO) member states recognised rare diseases as a global health priority for the first time. What does this mean and how could it impact access to life-saving treatment for the millions of people with rare diseases? #WHA78 buff.ly/CobLBZH
2
1
649
Jessica Davis Pluess retweeted
23 May 2025
Swiss pharma giant Novartis is diving into research on ageing to tap the growing, and potentially lucrative, market for drugs that help keep older adults healthy. #longevity #drugdevelopment #pharmaceuticals buff.ly/3GUUuyb
1
7
657
Jessica Davis Pluess retweeted
15 May 2025
United States President Donald Trump has taken aim at European governments for what he sees as undercharging for medicine at the expense of US patients. But raising prices in Europe would face pushback from lawmakers and the public. buff.ly/IEMsaej
2
1
1
561
Jessica Davis Pluess retweeted
15 May 2025
Over 30 years ago Michael Hall, a molecular biologist at @UniBasel_en, made a groundbreaking discovery of the gene Target of Rapamycin, or TOR. Today his seminal work is fuelling one of the fastest growing areas of healthcare research – longevity. 👉 buff.ly/66xMgYi
1
5
798
Jessica Davis Pluess retweeted
8 May 2025
With growing uncertainty in US financial markets and research funding, Chinese companies are swooping in to present themselves as stable, open partners to the Swiss biotech sector. buff.ly/XUZTRf1
3
3
616
Jessica Davis Pluess retweeted
7 May 2025
Michael Hall, a molecular biologist at the University of Basel, is a virtual unknown in today’s social media longevity scene. But his discovery of the gene Target of Rapamycin (TOR) is behind one of the most promising longevity drugs. #health #science buff.ly/Bmp5Xnf
1
3
695
Jessica Davis Pluess retweeted
2 May 2025
Are longevity clinics just hype or are they the secret to living a longer, healthier life? We visited some longevity clinics in Switzerland to probe the science behind the marketing brochures. Here's what we found out. #longevity #healthspan #health buff.ly/fxTTyKX
1
3
559
Jessica Davis Pluess retweeted
23 Apr 2025
Faced with a lack of breakthroughs in treating #mentalhealth disorders, older methods like electrical-based therapies are making a comeback — including in #Switzerland. This revival is reshaping approaches in #psychiatry and mental health treatment. buff.ly/tgCch3k
1
2
1
688
Jessica Davis Pluess retweeted
9 Dec 2024
Community pharmacies in many parts of the world are disappearing but not in Switzerland. Why is that? And, what does the future hold for Swiss pharmacies? buff.ly/3ZU0jBT
2
3
576
Jessica Davis Pluess retweeted
5 Dec 2024
In rich places like Switzerland, you wouldn’t generally expect your pharmacist to tell you they’ve run out of painkillers. But shortages of all types of medicines are becoming an issue. Is the situation similar where you are? Let us know. buff.ly/4ih7yL0
1
574
Jessica Davis Pluess retweeted
5 Dec 2024
Last year, Swiss health insurance companies spent CHF9 billion ($10.2 billion) on medicine for compulsory insurance, almost 6% more than in the previous year. And more than ever before. buff.ly/4iAQVKL
1
4
3
769
Jessica Davis Pluess retweeted
11 Nov 2024
Representatives of the scientific community warned against banning animal testing, arguing it would compromise important research, particularly in the biomedical field. buff.ly/3ABsSdg
1
1
610
Jessica Davis Pluess retweeted
12 Nov 2024
Switzerland consistently tops rankings of the most innovative countries, surpassing tech powerhouses like the United States and China. Why does it keep outpacing peers? #innovation #biotech buff.ly/3O7xFq5
2
9
973
Jessica Davis Pluess retweeted
8 Nov 2024
A second Trump presidency could be a boost for biomedical innovation, but it also risks eroding public trust in the pharmaceutical industry if science, trade and public health are sidelined. #bigpharma #globalhealth buff.ly/3Z7Skkh
1
2
1
1,244
Jessica Davis Pluess retweeted
30 Sep 2024
September marks World #Alzheimer's month and we bring you a story about the first new drug for Alzheimer’s disease in two decades: #Leqembi. @Swissmedic_ is expected to decide by the end of the year whether to approve this drug. ↩️ buff.ly/4eMjBxD
1
1
1
778
Jessica Davis Pluess retweeted
13 Sep 2024
Medicine can affect women differently than men, but rarely are sex and gender considered in the development of drugs. There’s now a movement, including in Switzerland, to change this. buff.ly/3ZhH19w
2
1
701
Jessica Davis Pluess retweeted
16 Aug 2024
For Swiss-based pharma giant Novartis, new US price-setting rules for ten major drugs are “not objective or transparent” and don’t reflect the true value of medicine. buff.ly/3yEgd8w
5
5
843
Jessica Davis Pluess retweeted
16 Aug 2024
Japan is the world’s third-largest pharmaceutical market, but it is increasingly being overlooked by international drugmakers when launching new drugs. The government is now fighting back. buff.ly/3AkmMNR
4
6
839
Medicare officials unveiled the results of the program’s first 10 drug price negotiations, despite the industry’s efforts to stop them. trib.al/P83uPCM
2
5
3,758